The Claim
Adding plasma copeptin to the DESIR clinical model improves the discrimination and reclassification of type 2 diabetes risk in women by increasing the C-statistic by 0.007 and the integrated discrimination improvement by 0.004, even after adjusting for glucose, hs-CRP, and urinary albumin excretion.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Including a blood marker called copeptin in a standard risk model for type 2 diabetes slightly improves its ability to distinguish which women will develop the disease, beyond what is already predicted by glucose, hs-CRP, and urinary albumin levels.
See the scientific wording
Adding plasma copeptin to the DESIR clinical model improves the discrimination and reclassification of type 2 diabetes risk in women by a statistically significant but clinically modest margin, increasing the C-statistic by 0.007 and the integrated discrimination improvement by 0.004, even after including glucose, hs-CRP, and urinary albumin excretion.
Higher levels of a stress-related hormone in the blood trigger the liver to release more sugar and change how the pancreas releases insulin, making it harder for the body to control blood sugar, especially in women because their bodies respond more strongly to this hormone.
What the research says
1 studyScientists found that adding a simple blood test for copeptin to existing diabetes risk models helps predict which women might get type 2 diabetes a little better — but not enough to change how doctors treat patients yet.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.